8-K: Q32 Bio Announces Mixed Results for Bempikibart Trials, Prioritizes Alopecia Areata Program

Q32 Bio reported positive results in an alopecia areata trial but failed to meet the primary endpoint in an atopic dermatitis study, leading to a strategic shift in focus.

Summary

• Q32 Bio announced topline results from two Phase 2a clinical trials for bempikibart, one in alopecia areata (AA) and another in atopic dermatitis (AD).
• The SIGNAL-AA trial showed that bempikibart led to a 16% mean reduction in SALT score at week 24, compared to a 2% reduction in the placebo group, with a p-value of 0.045.
• In the SIGNAL-AA trial, 9% of bempikibart patients achieved a SALT-20 at week 24, and 13% at week 26, compared to 0% in the placebo group.
• The SIGNAL-AD trial showed a 74% improvement in average EASI score from baseline for bempikibart, compared to 76% for the placebo group, which was not statistically significant.
• Bempikibart demonstrated favorable pharmacokinetics and target engagement in both trials, with reductions in Th2 and Th1 biomarkers.
• The company plans to expand the SIGNAL-AA trial with an additional 20 patients and defer enrollment in the ADX-097 ANCA-Associated Vasculitis trial to focus on the bempikibart AA program.

Sentiment

Score: 5

Explanation: The document presents mixed results, with positive findings in alopecia areata but a failure to meet the primary endpoint in atopic dermatitis. The strategic shift to focus on the AA program is a positive, but the need for potential future funding and the delay of the AAV trial temper the overall sentiment.

Positives

• Bempikibart showed statistically significant improvement in hair regrowth in the SIGNAL-AA trial, with a 16% mean reduction in SALT score compared to 2% for placebo.
• A meaningful percentage of patients in the SIGNAL-AA trial achieved a SALT-20 response, indicating significant hair regrowth.
• Bempikibart was observed to be safe and well-tolerated in both the SIGNAL-AA and SIGNAL-AD trials, with no serious adverse events or Grade 3 or higher adverse events related to treatment.
• Biomarker data from both trials showed that bempikibart effectively inhibits both TSLP and IL-7 signaling, as evidenced by changes in Th2 biomarkers and T-cells.
• The company is prioritizing the bempikibart program in alopecia areata, which has shown promising clinical activity.

Negatives

• The SIGNAL-AD trial failed to meet its primary endpoint, with no statistically significant difference between bempikibart and placebo in EASI score improvement.
• The SIGNAL-AA trial had to exclude a site due to protocol violations, which reduced the sample size and required a post-hoc analysis.
• The company is deferring enrollment in the planned Phase 2 clinical trial of ADX-097 in ANCA-Associated Vasculitis to focus on the bempikibart program.

Risks

• The company acknowledges that additional data or ongoing analyses may not support current beliefs and expectations for bempikibart.
• Future clinical studies may not be completed in a timely manner, may be more costly than expected, or may not yield anticipated results.
• The company may need additional funding to complete its clinical studies, which may not be available on favorable terms or at all.
• There is a risk that the company's product candidates may cause serious adverse side effects.
• The company faces significant competition and may not obtain U.S. or international marketing approval.

Future Outlook

The company plans to enroll approximately 20 additional patients in a Part B expansion of the SIGNAL-AA Phase 2a clinical trial to further evaluate bempikibart in AA, including a loading regimen. They will defer enrollment into the planned Phase 2 clinical trial of ADX-097 in ANCA-Associated Vasculitis to focus on the bempikibart AA program. The company expects initial data from the ADX-097 renal basket Phase 2 trial in 1H25 and topline results in 2H25.

Management Comments

• Jodie Morrison, CEO of Q32 Bio, stated they are pleased with the emerging signals observed in the SIGNAL-AA Phase 2a clinical trial and believe bempikibart has the potential to be an important new treatment option for alopecia areata.
• Jodie Morrison also expressed disappointment that the SIGNAL-AD trial did not achieve its primary endpoint and stated they plan to conduct a review to better understand the results.
• Jason Campagna, M.D., Ph.D., Chief Medical Officer of Q32 Bio, said they are encouraged by the findings from the SIGNAL-AA trial and look forward to advancing bempikibart as a potential treatment for AA.
• Brett King, M.D., Ph.D., of Dermatology Physicians of Connecticut, stated he is encouraged by the biomarker data, the safety profile of bempikibart, and the clinical signal of hair regrowth in patients.
• Shelia Violette, Ph.D., Co-Founder and Chief Scientific Officer of Q32 Bio, stated that the biomarker data represents a meaningful advancement in the clinical understanding of how inhibition of IL-7R can be leveraged to treat autoimmune and inflammatory diseases.

Industry Context

The results are being released in the context of a market where there is a need for safer alternatives to currently approved treatments for alopecia areata, such as JAK inhibitors, which have black box warnings. The company is positioning bempikibart as a potential option with a differentiated safety profile.

Comparison to Industry Standards

• The company compares the results of the SIGNAL-AA trial to the results of Phase 3 trials for Olumiant (baricitinib) and Litfulo (ritlecitinib), which are approved JAK inhibitors for alopecia areata.
• Olumiant showed a 13% SALT-20 response at week 24 in Phase 3 trials (7% and 11% placebo-adjusted), while Litfulo showed a 23% SALT-20 response (21% placebo-adjusted).
• Q32 Bio's bempikibart achieved a 9% SALT-20 response at week 24 and 13% at week 26 in the SIGNAL-AA trial, which is lower than the approved JAK inhibitors but may be considered promising given the safety profile and the difficult-to-treat patient population.
• The company highlights that the current treatments for alopecia areata require chronic treatment and have significant adverse events, suggesting a need for safer alternatives.

Stakeholder Impact

• Shareholders may react positively to the promising results in alopecia areata but negatively to the failed primary endpoint in atopic dermatitis.
• Patients with alopecia areata may benefit from the potential development of bempikibart as a new treatment option.
• Employees may be impacted by the shift in focus and the deferral of the ADX-097 AAV trial.
• The company's suppliers and partners may be affected by the changes in clinical trial priorities.

Next Steps

• The company plans to enroll approximately 20 additional patients in a Part B expansion of the SIGNAL-AA Phase 2a clinical trial.
• The company will conduct a review of the SIGNAL-AD results.
• The company will continue enrollment in the ongoing ADX-097 renal basket Phase 2 clinical trial.
• The company expects initial data from the ADX-097 renal basket Phase 2 trial in 1H25 and topline results in 2H25.

Key Dates

Keywords

bempikibart, alopecia areata, atopic dermatitis, SIGNAL-AA, SIGNAL-AD, IL-7R inhibitor, clinical trial, biomarkers, SALT score, EASI score, ADX-914, ADX-097